ArticleInternational journal of ophthalmology2017
Iontophoresis-assisted corneal crosslinking using 0.1% riboflavin for progressive keratoconus.
Article in International journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Transepithelial corneal cross-linking: a review.International ophthalmology · 2026Review
- Enhanced Riboflavin Stromal Delivery Using Microchannel-Assisted Iontophoresis for Corneal Crosslinking.Translational vision science & technology · 2025Article
- Demographic and topographic findings suggesting poor response to crosslinking-iontophoresis in patients with progressive keratoconus.International ophthalmology · 2025Article
- Keratoconus.Nature reviews. Disease primers · 2024Article
- Management of keratoconus: an updated review.Frontiers in medicine · 2023Review
- New perspectives in keratoconus treatment: an update on iontophoresis-assisted corneal collagen crosslinking.International ophthalmology · 2021Review
- Trans-epithelial corneal collagen cross-linking with iontophoresis for progressive keratoconus.International ophthalmology · 2019Article
- Current concepts in crosslinking thin corneas.Indian journal of ophthalmology · 2019Review
- Selected Medicines Used in Iontophoresis.Pharmaceutics · 2018Review
- Efficacy of iontophoresis-assisted epithelium-on corneal cross-linking for keratoconus.International journal of ophthalmology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo report the clinical results of iontophoresis-assisted epithelium-on corneal crosslinking (I-CXL) using 0.1% riboflavin in distilled water for progressive keratoconus.
methodsIn this prospective clinical study, we examined 94 eyes of 75 patients with progressive keratoconus who were treated with I-CXL using 0.1% riboflavin in distilled water. Best correct visual acuity (BCVA), Scheimpflug tomography, corneal topography, anterior segment optical coherence tomography, intraocular pressure, and endothelial cell density were evaluated at baseline and 1, 3, 6, 12, and 24mo after I-CXL.
resultsAfter 24mo I-CXL, compared to the level at baseline, BCVA significantly improved 0.14±0.07 (
conclusionI-CXL using 0.1% riboflavin halts keratoconus progression within 24mo, resulting in a significant improvement in visual and topographic parameters. Moreover, the depth of the demarcation line is similar to that previously reported in standard epithelium-off CXL procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.